Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Alkermes regains U.S. commercialization rights to Vivitrol from Cephalon

Dec. 3, 2008

Aeolus initiates animal study of AEOL-10150 in damage to the lungs due to radiation

Nov. 25, 2008

Novel NMDA receptor modulator shows neuroprotection against ethanol withdrawal, consumption

Nov. 25, 2008

Novel treatment options for iron overloading divulged in recent Xenon patents

Nov. 20, 2008

Nabi reports final results from phase II immunogenicity study of NicVAX

Oct. 31, 2008

Aphios receives phase I SBIR grant from NIDA to develop dronabinol for marijuana addiction

Oct. 29, 2008

PharmAthene initiates phase I trial of nerve agent bioscavenger Protexia

Oct. 29, 2008

Evotec reports results from phase I safety study of EVT-302

Oct. 29, 2008

Anti-flunitrazepam monoclonal antibody prevents sedative and cognitive effects of flunitrazepam

Oct. 23, 2008

Avigen initiates exploratory study of AV-411 in opioid withdrawal

Oct. 16, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...